Table 2.
Characteristics of the patients in Group 1a and Group 2a
| Group 1a 41 patients (46 eyes) |
Group 2a 31 patients (33 eyes) |
p | |
|---|---|---|---|
| Age, years | |||
| Mean ± SD | 70.7 ± 7.8 | 73.5 ± 7.7 | 0.127a |
| Gender, n (%) | 0.921b | ||
| Female | 19 (46.3) | 14 (45.2) | |
| Male | 22 (53.7) | 17 (54.8) | |
| Follow-up time, months | |||
| Median (IQR) | 32.00 (49.50) | 41.00 (53.00) | 0.223c |
| Planned extension period at V0, weeks | |||
| Median (IQR) | 8.64 (4.75) | 10.0 (6.00) | 0.940c |
| BCVA, logMAR | |||
| Median (IQR) | |||
| At presentation | 0.30 (0.56) | 0.30 (0.70) | 0.664c |
| At V0 | 0.45 (0.48) | 0.52 (0.40) | 0.719c |
| At V1 | 0.40 (0.58) | 0.70 (0.58) | 0.555c |
| At V2 | 0.40 (0.52) | 0.70 (0.59) | 0.216c |
| OCT, active/inactive | |||
| n (%) | |||
| At V0 | 11 (23.9)/35 (76.1) | 12 (36.4)/21 (63.6) | 0.342b |
| At V1 | 15 (32.6)/31 (67.4) | 20 (60.6)/13 (39.4) | 0.025b |
| At V2 | 13 (28.3)/33 (71.7) | 15 (45.5)/18 (54.5) | 0.181b |
| IVI count, n | |||
| Median (IQR) | |||
| Before V0 | 10.00 (9.50) | 13.00 (10.00) | 0.288c |
| Between V0 and V1 | 1.00 (0.25) | 0.00 (0.00) | < 0.001c |
| Between V1 and V2 | 2.00 (1.25) | 2.00 (2.00) | 0.856c |
| Between V0 and V2 | 3.00 (1.25) | 2.00 (2.00) | 0.001c |
Statistical significance is highlighted in bold
BCVA best-corrected visual acuity, IVI intravitreal injection, IQR interquartile range, logMAR logarithm of the minimum angle of resolution, OCT optical coherence tomography, SD standard deviation, V0 the last visit before the restriction period where the IVI at restriction period scheduled, V1 the first visit after the restriction period ends, V2 the last follow-up visit within six months after the restriction period ends
aIndependent-samples t test
bPearson Chi-square test with continuity correction
cMann–Whitney U test